153 related articles for article (PubMed ID: 18368291)
1. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Park BB; Im YH; Hwang IG; Lee SC; Ahn JS; Ahn MJ; Lim HY; Kang WK; Park K
Invest New Drugs; 2008 Aug; 26(4):387-92. PubMed ID: 18368291
[TBL] [Abstract][Full Text] [Related]
2. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.
Darnton SJ; Archer VR; Stocken DD; Mulholland PJ; Casson AG; Ferry DR
J Clin Oncol; 2003 Nov; 21(21):4009-15. PubMed ID: 14581424
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
6. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
[TBL] [Abstract][Full Text] [Related]
8. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
11. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
14. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer.
Serkies K; Jassem J; Dziadziuszko R
Int J Gynecol Cancer; 2006; 16(3):1152-6. PubMed ID: 16803499
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
Chen Y; Perng RP; Yang KY; Lin WC; Wu HW; Tsai CM; Whang-Peng J
Lung Cancer; 2000 Aug; 29(2):139-46. PubMed ID: 10963844
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy.
Huang J; Zhou Y; Zhang H; Qu T; Mao Y; Zhu H; Quan L; Xing P; Wang J; He J; Xu N; Sun Y
Med Oncol; 2013 Mar; 30(1):343. PubMed ID: 23263828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
